I have read your post right to your last exclamation marks, Scott999. I share your frustrations regarding the price fluctuations of the Pluristem share, but I think this comes with the territory. I have bought Pluristem shares at various price points. I have also seen strong fluctuations with other shares I own/have owned which have eventually leveled out at a higher value.
Given how far this company has come in the development of this new medical technology without having to rely on big pharma, etc., it would seem to me that management are fairly capable. It may take time for the research trials to be completed, but that is a necessary and indeed legislated feature of the process, i.e. bringing a new medical treatment/drug to market. Who knows what the future may hold.
Other posters have previously commented on Pluristem perhaps being under the radar and undervalued. The medical teams appear to competently carry out the necessary medical research (whilst being under scrutiny by those organizations giving grants). Therefore I cannot see much wrong with Mr Aberman as CEO trying to raise Pluristem’s profile. This is my opinion and I do not expect anybody to share it. I am a long term investor in Pluristem because I believe based on my reading of the relevant literature and reports (a big thank you to everyone on the board posting helpful links), that this is a company with very great potential.
News 
Market Data 
Discover 
